Literature DB >> 7675459

Genomic structure, expression and mutational analysis of the P15 (MTS2) gene.

S Stone1, P Dayananth, P Jiang, J M Weaver-Feldhaus, S V Tavtigian, L Cannon-Albright, A Kamb.   

Abstract

The P15 gene (MTS2) encodes a cyclin-dependent kinase (CDK) inhibitor with considerable sequence identity and biochemical similarity to the CDK inhibitor p16. It is closely linked to the P16 gene (MTS1) and is homozygously deleted in many tumor cell lines. These features suggest that p15 may be a tumor suppressor. We have determined the genomic structure of P15 and examined its pattern of mRNA expression. In addition, we have shown that ectopic expression of p15 inhibits growth of tumor-derived cell lines. We have also searched for P15 mutations in tumor cell lines and in 9p21-linked melanoma kindreds. Other than the previously described homozygous deletions, no mutations of P15 were found. Collectively, these observations suggest a role for p15 in growth regulation, but a limited role for p15 in tumor progression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7675459

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF.

Authors:  D E Quelle; M Cheng; R A Ashmun; C J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

Review 2.  Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database.

Authors:  Koh Miura; Kazuyuki Ishida; Wataru Fujibuchi; Akihiro Ito; Hitoshi Niikura; Hitoshi Ogawa; Iwao Sasaki
Journal:  Surg Today       Date:  2012-03-23       Impact factor: 2.549

3.  Conditional expression of the tumor suppressor p16 in a heterotopic glioblastoma model results in loss of pRB expression.

Authors:  Matthias Simon; Christian Simon; Gertraud Köster; Volkmar H J Hans; Johannes Schramm
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

4.  Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b).

Authors:  M Malumbres; I Pérez De Castro; M I Hernández; M Jiménez; T Corral; A Pellicer
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

5.  Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1.

Authors:  S Zhang; E S Ramsay; B A Mock
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

6.  Deletion and methylation of the tumour suppressor gene p16/CDKN2 in primary head and neck squamous cell carcinoma.

Authors:  M V González; M F Pello; C López-Larrea; C Suárez; M J Menéndez; E Coto
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

7.  Expression of p14(ARF), p15(INK4b), p16(INK4a) and skp2 increases during esophageal squamous cell cancer progression.

Authors:  Peng Bai; Xue Xiao; Juan Zou; Lin Cui; Tri M Bui Nguyen; Jinsong Liu; Jianguo Xiao; Bin Chang; Jin Wu; He Wang
Journal:  Exp Ther Med       Date:  2012-03-22       Impact factor: 2.447

8.  Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.

Authors:  K Laud; C Marian; M F Avril; M Barrois; A Chompret; A M Goldstein; M A Tucker; P A Clark; G Peters; V Chaudru; F Demenais; A Spatz; M W Smith; G M Lenoir; B Bressac-de Paillerets
Journal:  J Med Genet       Date:  2005-06-03       Impact factor: 6.318

9.  The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

Authors:  F J Stott; S Bates; M C James; B B McConnell; M Starborg; S Brookes; I Palmero; K Ryan; E Hara; K H Vousden; G Peters
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

10.  Comparative analysis of Homo sapiens and Mus musculus cyclin-dependent kinase (CDK) inhibitor genes p16 (MTS1) and p15 (MTS2).

Authors:  P Jiang; S Stone; R Wagner; S Wang; P Dayananth; C A Kozak; B Wold; A Kamb
Journal:  J Mol Evol       Date:  1995-12       Impact factor: 2.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.